Table 1 Design and baseline characteristic of trials included in the systematic review and meta-analysis
Source | No. of patients | Mean age, y | Sex (male, %) | Disease status | Intervention | Control | Follow-up (months) | Reporting outcomes | Jaded score |
|---|---|---|---|---|---|---|---|---|---|
Borchgrevink CF (1966) [7] | 100/100 | 57.4 | 100 | Coronary heart disease | 10 ml linseed oil | 10 ml corn oil | 10 | Cancer incidence; nonvascular death; total death | 2 |
Burr ML (1989) [8] | 1015/1018 | 56.5 | 100 | Recovered from myocardial infarction | Fish dietary | Non-fish dietary | 24 | Cancer incidence; Nonvascular death; total death | 1 |
de Lorgeril M (1994) [28] | 302/303 | 53.5 | 90.8 | Myocardial infarction within 6 months | Alpha-linolenic acid rich diet | Post-infarct prudent diet | 27 | Nonvascular death; total death | 1 |
Rossing P (1996) [9] | 18/18 | 33.0 | 65.5 | Diabetic nephropathy | N–3 fatty acids | Olive oil | 12 | Cancer incidence; | 4 |
Leng GC (1998) [29] | 60/60 | 65.7 | 68.3 | Stable intermittent claudication | Gamma-linolenic and eicosapentaenoic acids | Placebo | 24 | Nonvascular death; total death | 3 |
von Schacky (1999) [10] | 111/112 | 58.4 | 80.3 | Coronary artery disease | Fish oil concentrate (55% eicosapentaenoic and docosahexaenoic acids) | Placebo | 24 | Cancer incidence; | 5 |
GISSI-Prevenzione Investigators (1999) [11] | 5666/5658 | 60.0 | 85.3 | Recovered from myocardial infarction | N-3 polyunsaturated fatty acids witho or without vitamin E | Vitamin E or no treatment | 42 | Cancer incidence; Nonvascular death; total death | 3 |
Nilsen DWT (2001) [12] | 150/150 | 64.0 | 79.4 | Acute myocardial infarction | 4 g highly concentrated n-3 fatty acids | Corn oil | 24 | Cancer incidence; nonvascular death; total death | 2 |
Burr ML (2003) [13] | 1571/1543 | 61.1 | 100 | Angina | Two portions of oily fish each week, or to take three fish oil capsule daily with or without more fruit, vegetables and oats | no specific dietary advice with or without more fruit, vegetables and oats | 60 | Cancer incidence; nonvascular death; total death | 3 |
Raitt MH (2005) [14] | 100/100 | 62.5 | 86 | Implantable cardioverter defibrillator and a recent episode of sustained VT or VF | Fish oil, 1.8 g/d, 72% omega-3 PUFAs | Placebo | 24 | Cancer incidence; nonvascular death; total death | 4 |
Leaf A (2005) [30] | 200/202 | 65.5 | 83.1 | Implantable cardioverter defibrillator | Fish oil | Olive oil | 12 | Nonvascular death; total death | 3 |
Brouwer IA (2006) [15] | 273/273 | 61.5 | 84.5 | Implantable cardioverter defibrillator | 2 g/d of fish oil | Placebo | 12 | Cancer incidence; nonvascular death; total death | 4 |
JELIS Ivestigators (2007) [16] | 9326/9319 | 61.0 | 31.5 | Total cholesterol of 6 · 5 mmol/L or greater | EPA with statin | Statin | 55.2 | Cancer incidence; nonvascular death; total death | 5 |
GISSI-HF investigators (2008) [31] | 3494/3481 | 67.0 | NG | Chronic heart failure | N-3 PUFA 1 g daily | Placebo | 46.8 | Nonvascular death; total death | 5 |
OMEGA Study Group (2010) [32] | 1919/1885 | 64.0 | 74.4 | Recovered from myocardial infarction | 1 g omega-3 acid ethyl esters-90 | Olive oil | 12 | Nonvascular death; total death | 4 |
Einvik G (2010) [33] | 282/281 | 70.1 | 100 | Hypercholesterolemia (> 6.45 mmol/l) | 2.4 g n-3 PUFA | Corn oil | 36 | Nonvascular death; total death | 4 |
SU.FOL.OM3 Collaborative Group (2010) [17] | 1253/1248 | 60.6 | 79.4 | with a history of myocardial infarction, unstable angina, or ischaemic stroke | Omega 3 fatty acids with or without vitamin B | Placebo or vitamin B | 56.4 | Cancer incidence; total death | 5 |
Alpha Omega Trial Group (2010) [34] | 2404/2433 | 69.0 | 78.2 | Recovered from myocardial infarction | EPA and DHA with or without ALA | ALA or placebo | 40.8 | Nonvascular death; total death | 4 |
The ORIGIN Trial Investigators (2012) [35] | 6281/6255 | 63.5 | 65.1 | High risk for cardiovascular events | N–3 fatty acids | Placebo | 74.4 | Nonvascular death; total death | 4 |